Cart
Orders
Not available here
Product Overview
JUVÉDERM is a collection of injectable hyaluronic acid (HA) dermal fillers developed by Allergan Aesthetics, an AbbVie company. The JUVÉDERM VYCROSS range includes VOLBELLA, VOLIFT, VOLUMA, and VOLUX, four cross-linked HA gel formulations designed for different facial correction and volumization requirements. Each formulation contains 0.3% lidocaine hydrochloride and has distinct HA concentrations, material characteristics, and intended applications.
Manufactured in France, these JUVÉDERM fillers use VYCROSS technology to create cohesive, viscoelastic hyaluronic acid gels with formulation-specific properties. The four products cover applications ranging from fine-line correction and lip enhancement to facial volume restoration and jawline definition, subject to their respective approved indications.
This JUVÉDERM product page brings together VOLBELLA, VOLIFT, VOLUMA, and VOLUX for professional buyers comparing HA concentration, lidocaine content, formulation characteristics, and packaging specifications. Product selection and clinical use must follow the applicable instructions for use and local medical device regulations.
Key Features
- Four Specialized HA Fillers: VOLBELLA, VOLIFT, VOLUMA, and VOLUX offer different hyaluronic acid concentrations and gel characteristics for distinct facial aesthetic indications.
- VYCROSS Technology: The formulations use Allergan's VYCROSS cross-linking technology, which combines hyaluronic acid chains of different molecular weights to produce cohesive, viscoelastic injectable gels.
- 0.3% Lidocaine: All four formulations contain 3 mg/mL lidocaine hydrochloride, a local anesthetic incorporated to help reduce discomfort associated with treatment.
- Distinct HA Concentrations: The range includes 15 mg/mL, 17.5 mg/mL, 20 mg/mL, and 25 mg/mL formulations, allowing healthcare professionals to distinguish products by composition and intended application.
- Pre-Filled Syringe Presentation: The referenced manufacturer instructions describe sterile, single-use 1 mL pre-filled syringes, with two syringes per standard box and accompanying sterile needles.
Composition & Specifications
JUVÉDERM VOLBELLA, VOLIFT, VOLUMA, and VOLUX are based on non-animal-origin, cross-linked hyaluronic acid formulated as sterile injectable gels. Although they share the same lidocaine concentration and VYCROSS technology platform, their HA concentrations and material properties differ.
| Specification | Details |
|---|---|
| Brand | JUVÉDERM |
| Product Range | VOLBELLA / VOLIFT / VOLUMA / VOLUX |
| Product Category | Injectable Hyaluronic Acid Dermal Fillers |
| Primary Material | Cross-Linked Hyaluronic Acid |
| HA Origin | Non-Animal Origin |
| Cross-Linking Technology | VYCROSS |
| Cross-Linking Agent | BDDE (1,4-Butanediol Diglycidyl Ether) |
| HA Concentration | 15–25 mg/mL, Depending on Formulation |
| Lidocaine Content | 0.3% (3 mg/mL) |
| Gel Formulation | Sterile, Cross-Linked, Viscoelastic HA Gel |
| Syringe Volume | 1 mL per Pre-Filled Syringe |
| Standard Box Configuration | 2 × 1 mL Pre-Filled Syringes |
| Manufacturer | Allergan |
| Brand Company | Allergan Aesthetics, an AbbVie Company |
| Country of Manufacture | France |
| Intended Users | Authorized and Appropriately Trained Healthcare Professionals |
Specifications refer to the international VOLBELLA, VOLIFT, VOLUMA, and VOLUX formulations with lidocaine. Packaging, labeling, and regulatory indications may differ by market. US-specific XC presentations should be evaluated against their own official documentation.
How JUVÉDERM VYCROSS Technology Works
Hyaluronic acid is a naturally occurring glycosaminoglycan found in the extracellular matrix of human tissues. Its ability to associate with water contributes to tissue hydration and the mechanical properties of the skin.
In injectable dermal fillers, hyaluronic acid is chemically cross-linked to form a more persistent gel network. This modification helps the material resist rapid degradation and enables the gel to provide temporary physical support or volume within the treated tissue.
JUVÉDERM VYCROSS technology combines hyaluronic acid chains of different molecular weights within a cross-linked gel structure. The resulting material is designed to provide cohesion, smoothness, and viscoelastic characteristics appropriate to the individual formulation.
Viscoelasticity describes a material's combined elastic and viscous responses to mechanical forces. In dermal fillers, these properties influence how a gel behaves under compression, deformation, and movement. However, HA concentration alone does not determine firmness, lifting capacity, or clinical performance.
The four JUVÉDERM formulations are engineered for different clinical requirements. Their distinct material properties and approved indications are more meaningful for professional assessment than concentration alone.
All four products additionally contain lidocaine hydrochloride. Lidocaine temporarily inhibits voltage-gated sodium channels in sensory nerves, helping reduce discomfort during administration.
Available JUVÉDERM Variants
The JUVÉDERM VYCROSS collection includes formulations with different HA concentrations, intended treatment areas, and structural characteristics. The following comparison covers the four products included on this page.
| Product | HA Concentration | Lidocaine | Principal Application | Syringe Volume |
|---|---|---|---|---|
| JUVÉDERM VOLBELLA | 15 mg/mL | 0.3% | Fine Lines, Moderate Skin Depressions, and Lip Enhancement | 1 mL |
| JUVÉDERM VOLIFT | 17.5 mg/mL | 0.3% | Deeper Facial Wrinkles, Facial Contouring, and Lip Enhancement | 1 mL |
| JUVÉDERM VOLUMA | 20 mg/mL | 0.3% | Facial Volume Restoration and Contouring | 1 mL |
| JUVÉDERM VOLUX | 25 mg/mL | 0.3% | Jawline Definition and Lower-Face Volume Correction | 1 mL |
JUVÉDERM VOLBELLA — 15 mg/mL
JUVÉDERM VOLBELLA with Lidocaine is a cross-linked hyaluronic acid filler containing 15 mg/mL HA and 0.3% lidocaine hydrochloride. It is designed for correction of fine lines and moderate skin depressions, as well as lip enhancement.
The formulation is associated with relatively fine facial correction requirements, including superficial facial lines and lip contour or volume concerns. Its approved indications and permitted treatment areas depend on the applicable market-specific instructions for use.
JUVÉDERM VOLIFT — 17.5 mg/mL
JUVÉDERM VOLIFT with Lidocaine contains 17.5 mg/mL cross-linked hyaluronic acid and 0.3% lidocaine hydrochloride. It is intended for correction of deeper skin depressions and selected facial contour or volume deficiencies.
Compared with VOLBELLA, VOLIFT addresses different facial correction requirements, including deeper wrinkles and volume-related changes involving areas such as the lips and lower face, where supported by the relevant product labeling.
JUVÉDERM VOLUMA — 20 mg/mL
JUVÉDERM VOLUMA with Lidocaine is a hyaluronic acid dermal filler containing 20 mg/mL HA and 0.3% lidocaine hydrochloride. It is specifically associated with facial volume restoration and contour enhancement.
The formulation is designed to provide physical volume and support in indicated facial areas, including the cheek and midface regions. VOLUMA differs from the fine-line-oriented formulations through its intended volumizing function and associated material characteristics.
JUVÉDERM VOLUX — 25 mg/mL
JUVÉDERM VOLUX is a cross-linked hyaluronic acid filler containing 25 mg/mL HA and 0.3% lidocaine hydrochloride. It is formulated for structural facial correction, particularly jawline definition and lower-face contouring.
VOLUX is designed with material characteristics appropriate to applications requiring substantial gel structure and projection. Its higher HA concentration distinguishes it compositionally from VOLBELLA, VOLIFT, and VOLUMA, although concentration should not be interpreted as a standalone measure of clinical performance.
The four formulations have different indications and material characteristics. They should not be considered interchangeable solely on the basis of HA concentration. Treatment planning and product selection are responsibilities of appropriately qualified healthcare professionals.
Packaging & Product Presentation
The referenced manufacturer instructions describe JUVÉDERM VOLBELLA, VOLIFT, VOLUMA, and VOLUX as sterile injectable gels supplied in graduated, pre-filled, single-use syringes.
| Product | Standard Box | Needles Included |
|---|---|---|
| VOLBELLA | 2 × 1 mL Syringes | 4 × 32G 1/2" Needles |
| VOLIFT | 2 × 1 mL Syringes | 4 × 30G 1/2" Needles |
| VOLUMA | 2 × 1 mL Syringes | 4 × 27G 1/2" Needles |
| VOLUX | 2 × 1 mL Syringes | 4 × 27G 1/2" Needles |
Standard manufacturer packaging also includes product instructions and traceability labels. The gel is supplied ready for professional use in its original sterile syringe presentation.
The packaging details above describe documented international presentations. Box quantities, supplied accessories, and labeling can vary by market or SKU. Buyers should verify whether a TEOSQUARE listing refers to an individual syringe or a complete manufacturer box.
Storage & Handling
Manufacturer instructions for the referenced JUVÉDERM VYCROSS formulations specify controlled storage conditions to preserve product integrity. The exact requirements printed on the supplied packaging and market-specific instructions for use take precedence.
- Storage Temperature: Store under the temperature conditions specified in the corresponding manufacturer's instructions. A range of 2°C to 25°C is documented for the referenced VOLIFT formulation.
- Physical Protection: Protect the original packaging from excessive heat, freezing, and unnecessary mechanical damage.
- Sterile Presentation: Keep the product in its original packaging until use. Do not use a syringe if its sterile barrier is damaged.
- Single-Use Product: Pre-filled syringes are intended for single use and must not be reused or resterilized.
- Traceability: Verify the product name, formulation, batch number, expiration date, and labeling before professional use.
Storage conditions must be checked separately for VOLBELLA, VOLIFT, VOLUMA, and VOLUX using the instructions supplied with the specific market version. Do not assume identical temperature limits across every registered presentation.
Safety & Professional Use
JUVÉDERM injectable dermal fillers are medical devices intended for use by appropriately trained and authorized healthcare professionals. Product selection, patient assessment, administration, and follow-up must comply with the relevant instructions for use and applicable regulations.
Commonly reported reactions associated with hyaluronic acid filler treatment include swelling, redness, tenderness, pain, firmness, bruising, and localized irritation. Other complications may include infection, inflammatory reactions, nodules, and hypersensitivity.
Accidental injection into a blood vessel can cause vascular occlusion, tissue ischemia, necrosis, visual impairment including blindness, or other serious complications. These risks require appropriate professional training, anatomical knowledge, and access to established complication-management procedures.
Patients with known hypersensitivity to hyaluronic acid, lidocaine, or relevant bacterial proteins, as well as patients with certain medical conditions, may be unsuitable for treatment. Contraindications and precautions differ between products and jurisdictions.
JUVÉDERM VOLBELLA, VOLIFT, VOLUMA, and VOLUX must be assessed according to their individual regulatory indications. Approval of one formulation or its US-specific XC counterpart does not automatically establish equivalent authorization for another formulation or country.
Product information is provided for professional identification and comparison. It does not constitute a treatment recommendation, establish individual patient suitability, or replace official manufacturer labeling.
Frequently Asked Questions
What is the difference between JUVÉDERM VOLBELLA, VOLIFT, VOLUMA, and VOLUX?
The four JUVÉDERM fillers differ in HA concentration, gel characteristics, and intended applications. VOLBELLA contains 15 mg/mL HA for fine-line correction and lip enhancement. VOLIFT contains 17.5 mg/mL for deeper facial correction and contouring. VOLUMA contains 20 mg/mL for facial volume restoration, while VOLUX contains 25 mg/mL and is designed particularly for jawline definition.
Do all four JUVÉDERM formulations contain lidocaine?
Yes. The VOLBELLA, VOLIFT, VOLUMA, and VOLUX formulations described on this page each contain 0.3% lidocaine hydrochloride, equivalent to 3 mg/mL. Lidocaine is incorporated to help reduce discomfort during treatment.
What is VYCROSS technology in JUVÉDERM fillers?
VYCROSS is Allergan's hyaluronic acid cross-linking technology that combines HA chains of different molecular weights. It is used to create cohesive, viscoelastic injectable gels with characteristics tailored to individual JUVÉDERM formulations.
How many syringes are included in a standard JUVÉDERM box?
The referenced international manufacturer presentations of VOLBELLA, VOLIFT, VOLUMA, and VOLUX contain two pre-filled 1 mL syringes per box, together with sterile needles and product documentation. Packaging may differ by market or commercial SKU.
Does a higher HA concentration mean a firmer JUVÉDERM filler?
Not necessarily. Although HA concentration is an important formulation parameter, gel firmness and mechanical behavior also depend on cross-linking, molecular structure, cohesivity, and other rheological properties. The four JUVÉDERM products should be compared using their documented material characteristics and intended applications rather than HA concentration alone.
Are JUVÉDERM VOLBELLA, VOLIFT, VOLUMA, and VOLUX interchangeable?
No. These formulations have distinct material properties, indications, and labeling requirements. Their use must be determined by an appropriately qualified healthcare professional according to the individual product's instructions for use and applicable regulations.